Is Charles River Laboratories Stock Outperforming the S&P 500? Charles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook. Barchart · Sep 27
Charles River Laboratories Stock: Is Wall Street Bullish or Bearish? Charles River Laboratories has continued to underperform the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects. Barchart · Nov 21, 2025
Charles River Beat Expectations But Why Is The Stock Falling? Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company’s strategic review. Benzinga · Nov 5, 2025
Is Charles River Laboratories Stock Underperforming the Nasdaq? Charles River Laboratories has significantly underperformed the Nasdaq Composite over the past year, yet analysts remain cautiously optimistic about the stock’s prospects. Barchart · Sep 24, 2025
Charles River Laboratories Stock: Analyst Estimates & Ratings Despite Charles River Laboratories’ weak performance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects. Barchart · Aug 27, 2025
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released second-quarter 2025 earnings. Benzinga · Aug 6, 2025
Do Wall Street Analysts Like Charles River Laboratories Stock? Charles River Laboratories stock has notably lagged behind the broader market over the past year, yet analysts remain moderately optimistic about the stock’s prospects. Barchart · May 27, 2025
Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance. Barchart · Feb 26, 2025
Charles River Laboratories Earnings Preview: What to Expect Charles River Laboratories is poised to release its second-quarter earnings next month, and analysts expect a double-digit earnings dip. Barchart · Jul 29, 2024
Vaccines are still tested with horseshoe crab blood. The industry is finally changing The horseshoe crab bleeding industry is in transition. One biomedical company agreed to more oversight, and a regulatory group is paving the way for drug companies to use animal-free alternatives. WEKU · Sep 23, 2023
Fate of 1,000 trafficked lab monkeys at center of US investigation in limbo Long-tailed macaques at risk of being killed, or laundered or re-trafficked if returned to Cambodia, animal welfare groups say The Guardian - US · Mar 20, 2023
Analyst Ratings for Charles River Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: Benzinga · May 24, 2022
Benzinga · May 4, 2022 Charles River: Q1 Earnings Insights Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · May 3, 2022 Preview: Charles River's Earnings Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River will report an earnings per share (EPS) of $2.71.
Benzinga · Apr 25, 2022 Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know Wells Fargo has decided to maintain its Overweight rating of Charles River (NYSE:CRL) and lower its price target from $390.00 to $325.00. Shares of Charles River are trading down 7.96% over the last 24 hours, at $251.29 per share.
Benzinga · Apr 25, 2022 What 6 Analyst Ratings Have To Say About Charles River Analysts have provided the following ratings for Charles River (NYSE:CRL) within the last quarter:
Benzinga · Apr 6, 2022 Charles River Buys Contract Vivarium Research Services Firm In $295M Deal Charles River Laboratories International Inc (NYSE: CRL) has acquired Explora BioLabs Holdings Inc, a provider of contract vivarium research services,
Benzinga · Feb 17, 2022 Charles River Earnings Perspective: Return On Invested Capital According to Benzinga Pro, during Q4, Charles River (NYSE:CRL) earned $139.83 million, a 32.97% increase from the preceding quarter. Charles River also posted a total of $905.05 million in sales, a 1.02% increase since Q3.
Benzinga · Feb 16, 2022 Charles River's Q4 Earnings Beats Street Expectation, Reaffirms FY22 Outlook Charles River Laboratories International Inc's (NYSE: CRL)
Benzinga · Feb 16, 2022 Recap: Charles River Q4 Earnings Charles River (NYSE:CRL) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.